Welcome to our dedicated page for OMADA HEALTH SEC filings (Ticker: OMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omada Health, Inc. (Nasdaq: OMDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a virtual-first, between-visit healthcare provider focused on cardiometabolic and musculoskeletal conditions, Omada uses these filings to report on its financial condition, operations, and material events related to its digital chronic care platform.
Investors can review current reports on Form 8-K, which Omada uses to furnish press releases announcing quarterly results and other significant developments. For example, recent 8-K filings reference earnings press releases for periods in which the company reported revenue, member growth, and updates on its GLP-1-related offerings and AI capabilities. These current reports help readers connect headline financial and operational metrics to the underlying SEC record.
In addition to 8-Ks, Omada’s periodic reports on Form 10-Q and Form 10-K (accessible through the SEC and linked from this page when available) typically contain more detailed information on revenue composition, cost structure, research and development spending, and risks associated with its virtual care and GLP-1 programs. These filings are particularly relevant for understanding how Omada’s cardiometabolic and musculoskeletal programs, GLP-1 Care Tracks, and prescribing and medication management capabilities are reflected in its financial statements and risk disclosures.
Stock Titan enhances this information with AI-powered summaries that explain key points from lengthy filings, helping readers quickly identify sections related to Omada’s chronic care model, GLP-1 initiatives, and digital health operations. Users can also monitor updates to OMDA’s filings in near real time, including new 8-Ks, 10-Qs, 10-Ks, and other relevant forms, to follow how the company reports on its performance and material events over time.
Omada Health insider sale: The Form 4 shows Wei-Li Shao, President and officer of Omada Health, sold 2,407 shares of common stock on 09/05/2025 at a price of $24.28 per share. After the sale, Shao beneficially owned 76,540 shares, reported as direct ownership. The filing was signed by an attorney-in-fact on 09/09/2025.
Omada Health, Inc. Schedule 13G shows that a set of related reporting persons (U.S. Venture Partners X, L.P.; USVP X Affiliates, L.P.; Presidio Management Group X, L.L.C.; and Casey M. Tansey) report collective beneficial ownership of the company's common stock. The filings report 4,571,769 shares held directly by USVP X and an additional 146,257 shares held by USVP X Affiliates, for a combined reported position of 4,718,026 shares. The filing states this represents approximately 8.2% of the outstanding common stock based on 57,574,921 shares of common stock outstanding used for the calculation. The reporting persons disclaim group status and clarify that Presidio Management Group X, L.L.C. acts as general partner and certain named individuals may be deemed to share voting and dispositive power, while each disclaims beneficial ownership except to the extent of any pecuniary interest.
The filing is a Schedule 13G disclosing that Andreessen Horowitz-related entities and principals report beneficial ownership in Omada Health, Inc. (OMDA) as of June 30, 2025. Andreessen Horowitz Fund IV, L.P. directly holds 4,210,602 shares (reported as 7.6% of the class) and AH Parallel Fund IV, L.P. directly holds 403,972 shares (reported as 0.7% of the class), producing an aggregate reported position of 4,614,574 shares, equal to 8.3% of outstanding common stock based on 55,744,340 shares outstanding per the issuer prospectus dated June 5, 2025. The filing identifies Andreessen and Horowitz as individuals with shared voting and dispositive power over the aggregated holdings and includes powers of attorney and a joint filing agreement.
Revelation-affiliated entities and two managing members reported beneficial ownership positions in Omada Health's common stock. Michael Boggs and Scott Halsted each report beneficial ownership of 5,208,034 shares, representing 9.1% of the outstanding stock, while Revelation Healthcare Fund IV reports 3,095,306 shares (5.4%). Several Revelation entities report smaller positions (0.9%–2.3%).
The statement shows these reporting persons have sole voting and sole dispositive power over the shares disclosed and uses a public share count of 56,929,340 shares to calculate percentages. The filing is a disclosure of ownership levels by related funds and their managers; it does not announce transactions, changes in control, or other operational developments within the company.
Omada Health reported accelerating commercial growth with materially stronger liquidity following its IPO. Revenue rose to $61.4 million for the quarter and $116.3 million for the six months, increases of 49% and 52% year-over-year, driven by services and connected-device sales. Gross profit expanded while operating loss narrowed to $4.3 million for the quarter and $12.7 million for six months, reflecting higher revenue and continued investment in R&D, sales and marketing, and G&A.
The company closed an IPO that generated $151.6 million of net proceeds and converted all redeemable convertible preferred stock into common shares, leaving cash and cash equivalents of $223.1 million and eliminating prior preferred-stock balances and related warrant liabilities. Omada reported over 752,000 enrolled members and maintains a $30.0 million term facility (repaid subsequent to period). Despite improved liquidity and revenue momentum, the company remains loss-making with a substantial accumulated deficit.